

Highlights of FY2020 Business Results

(Year ended March 31, 2021)



Contents

I.	Summary of Results	3
II.	FY2021 Forecasts	8
III.	Management Strategy	11



I. Summary of Results



Sales, Income

	FY20	10		EVA	FY2020					
	FY2U)19		FY2	VO	Y		cast*)		
	Amount	% of Sales	Amount	% of Sales	Amount	Change (%)	Amount	Achieved (%)		
Net Sales	31,756	100	31,541	100.0	(214)	(0.7)	31,000	101.7		
Pharmaceutical products	30,632	96.5	30,423	96.5	(208)	(0.7)	_			
Others	1,123	3.5	1,117	3.5	(6)	(0.5)				
Cost of sales	19,200	60.5	20,097	63.7	896	4.7	_			
SC & A avpansas	12,190	38.4	10,879	[+3.2p] 34.5	(1 211)	(10.9)				
SG&A expenses	12,190	38.4	10,879	54.5 [∆3.9p]	(1,311)	(10.8)				
Operating income	364	1.1	564	1.8	199	54.8	200	282.3		
Income before income taxes and minority interests	732	2.3	713	2.3	(18)	(2.6)	_			
Net income attributable to owners of the parent	436	1.4	495	1.6	58	13.4		x10		

*Revised forecast issued on Oct 30, 2020.



(¥mn)

Pharmaceutical Sales

							(¥mn)
	FY20 1	19]	F Y2020		FY2020 Fo	orecast**
		% of		% of	YOY		Achieved
	Amount	Sales	Amount	Sales	(%)	Amount	(%)
Total (① + ②)	27,788	100.0	27,322	100.0	(1.7)	27,040	101.0
1) Generics	26,425	95.1	25,532	93.4	(3.4)	25,190	101.4
To medical institutions	25,442		24,531		(3.6)	24,200	101.4
To other makers*	983		1,000		1.8	990	101.1
Amlodipine	2,646		2,482		(6.2)	2,370	104.7
Lansoprazole	1,229		949		(22.8)	990	95.9
Donepezil	1,005		824		(18.0)	850	97.0
Rabeprazole	1,311		1,416		8.1	1,360	104.2
Limaprost Alfadex	943		728		(22.8)	740	98.4
Others	19,290		19,131		(0.8)	18,880	101.3
② Proprietary products and new drugs	1,362	4.9	1,790	6.6	31.4	1,850	96.8
Uralyt	842		730		(13.3)	740	98.8
Others	520		1,059		x2	1,110	95.5
Total (① + ③)	27,322		26,696	_	(2.3)	26,290	101.5
③ Generics (ODM)	896		1,164		29.9	1,100	105.8

* Includes exports

** Revised forecast issued on Oct 30, 2020.




Balance Sheet

					(¥mn)
	FY2019	FY2020	Change	Components	
				Cash, deposits	505
				Notes, accounts receivable-trade	660
Current assets	29,314	30,446	1,132	Inventories	235
				Buildings and structures	(381)
Non-current assets	16,547	16,676	129	Investment securities	173
Total assets	45,862	47,124	1,261		
				Notes, accounts payable-trade	344
				Short-term loans payable	(256)
Current liabilities	13,739	14,102	363	Accrued expenses	(85)
Non-current liabilities	14,730	15,006	276	Long-term loans payable	577
				Unrealized holding gains or loss on	
Net assets	17,392	18,014	622	securities	143
Liabilities, net assets	45,862	47,124	1,261		

	FY2019	FY2020	Change
Current ratio (x)	2.13	2.16	0.03
Capital-to-asset ratio (%)	37.9	38.2	0.3



Cash Flow



7

II. FY2021 Forecasts



Sales, Income, R&D Expenses and Other

					(¥mn)			
	FY20	20	FY2021 (Forecast)					
		% of		% of	YOY			
	Amount	Sales	Amount	Sales	(%)			
Net Sales	31,541	100.0	31,000	100.0				
Operating income	564	1.8	350	1.1				
Income before income taxes								
and minority interests	713	2.3						
Net income attributable to								
owners of the parent	495	1.6	80	0.3				

Note:

We plan to apply "the Accounting Standards for Revenue Recognition (ASBJ Statement No. 29)" from the FY2021, and the consolidated financial forecast for the FY2021 incorporates these changes. Therefore, year-on year rate from the actual results for the FY2021 before the application of the standards, etc. is not stated.

Main factors driving changes in net sales

- (-) NHI drug price reduction in April 2021
- (-) Tendency for patients to refrain from medical examinations in the midst of the COVID-19 pandemic.
- (+) Sales channel diversification efforts
- (+) Full-year contributions from Klaricid
- (+) Launching new generics

Main factors affecting income

(-) Decline in gross profit caused by NHI drug price reduction

11

- (-) R&D expenses for phase 1 trial for NC-2800, which supported by public funds
- (+) Full-year contributions from group structural reforms

			(¥mn)
	FY2020	FY2021 (Forecast)	YOY
R&D expenses	1,998	2,400	401
Capital expenditure	676	1,000	323
Depreciation and amortization	1,192	1,300	107



Pharmaceutical Sales Forecast

FY2021 (Forecast) **FY2020** YOY % of Sales % of Sales Amount %) Amount Total 27,322 100.0 26,550 100.0 25,532 24,700 93.0 Generics 93.4 To medical institutions 24,531 23,600 To other makers* 1.000 1,100 **Proprietary products and new drugs** 1,790 6.6 1,850 7.0 Uralyt 730 580 Others 1.059 1,270 25,410 26,696 **Total Generics (ODM)** 1,164 710

* Includes exports

Note:

We plan to apply "the Accounting Standards for Revenue Recognition (ASBJ Statement No. 29)" from the FY2021, and the consolidated financial forecast for the FY2021 incorporates these changes. Therefore, year-on year rate from the actual results for the FY2021 before the application of the standards, etc. is not stated.



(¥mn)

III. Management Strategy



Three Plus 1 Principal Goals

Overview

Business strategy by Three Principal Goals

- By fulfilling our three principal goals, we will establish a proprietary business model.
- To make that growth sustainable, we are expanding our business internationally.



Goal 1: Generics

Develop unique business by differentiating our products and enhance cost competitiveness.

Goal 2: Alkalizer

Apply the results of clinical research on alkalization therapy to the fullest extent possible.

Goal 3: Drug discovery

Simultaneously reduce risk, improve drug discovery efficiency, and launch new drugs on a global scale by focusing on exploratory research and out-licensing our findings at an early stage.

Plus 1: Apply our three goals to overseas markets centered on Asia



Management Strategy 1

We are developing a multi-faceted strategy for expanding our Pharmaceutical Products business that is grounded in our three plus 1 principal goals.

Ou	Our Growth Matrix Drug discovery From manufacture to sale of pharmaceu							rmaceuticals			
		Existing produ				New	product				
		Existing technol		New technology							
Present market	Present	Generic drugs Improvement in Group-wide productivity enhance profitability by value added proc		De	velopme	oduction of new products (new and long-listed drugs) lopment and stable supply of valuable products through opriate life cycle management.					
market	Present field of R&D	Strengthening and streamlining o Reduction of manufacturing costs through Vietnam factory and expansion of insource manufacturing at both domestic and overs	n use of the red	ins		Innovative allergy screening kit ch DropScreen [™] ; joint marketing in Japan with FILM Wako Pure Chemical Corporation. Drug discovery					
Ι	Ne	Export We are currently selling five products (pro products and generic drugs), in three coun			Expansion in scope of drug discovery to include drugs related to the central nervous system while focusing on treatments for hyperuricemia and pain; preparation for phase 1 clinical trials concerning NC-2800; crucial stage for out-licensing activities						
New market	New field of R&D	Overseas rollout of allergen measuring devices Out-licensing DP3000 to Chinese					t of efficient clin	new technologies ical development usi ques and real-world	ng new		
¥	&D	company and collection of royalties. Drug repositioning New indications for Soleton and Calvan	ancer agents, promotion of clinical possibility biting the progress of chronic kidney the digi				ration of s related to ll medical y business				

Management Strategy 2-a

Many parallel activities leads to achieve our three plus 1 principal goals. We show timeline from FY2021—2030.

Goal	Contents	Activity	20	21	20	022	20	23	20	024	2025		2026	2	027	20	28	202	29	2030
Generics	For domestic market	Launch value-added generics and introduce products from other company						Aim	to la	unch t	two or mo	ore v	value- ad	led pr	oducts	s per ye	ear.			
		DFP-17729		se 1/2 preatic er			P	hase 3			Applic	ation	n, approv	al, an	d laun	ching				
Alkalizer		Consider expanding applications to include additional chronic kidney disease-related indications		DA nselin sultati		indic	ation	s, mov	ve to c	clinica	apeutic u 1 phase ial terms a				-			vorld	appr laun	lication, oval, and ching ith AI.)
		For functional foods and health foods			Lau -202	nching					FY2022-		Seque		y launc	h two o				

Management Strategy 2-b

Goal	Contents	Activity	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
		NC-2800: Conduct phase 1/ 2a trials, out-licensing		phase 1/2 CiCLE p	a trials in ac rogram		duct phase 2 the licensee					
Drug	Licensing out activities	NC-2600: Out-license for new indications					nse as a treat vement of mi		ronic coughi	ing and contr	tibute to ear	nings
discovery	7	NC-2500/NC-2700: Progress to phase encompassing out- licensing activities and development			2	-	C-2500 for r he developm			ion to gout a aising, etc.	nd hyperuric	emia.
	Create new compound	Discover new compounds by utilizing AI	Create new	compoun	ids phas	linical e/ nse out		scovery of 1 w methods	new compou	nds continuc	usly throug	 n
	Pharmaceuticals	From export to local development and production	Sell five pr to 4 countri		Sell ten pr countries Manufactu six produc in Vietnar	ts devel		number of c a business m	ountries in w	expanding ou hich these pro ed on highly p	ducts are sold	
Overseas business		Licensing business of DP3000 and IgE NC in the Chinese market	Intermediat goods assoc with IgE N	ciated	Addition measurem		ved items f	or		subsequent ad measurement	dition of appi	oved
	Diagnostics	Sales expansion of Drop Screen		nestic opment of eas reagen	launching f an	series of mea Sequentia	ous business suring reagen I launch in mericas and	ts Europe	rough			

Generic Business

Responding to rapid changes in business environment and converting to a business structure that will achieve sustainable growth in all environments.

Development	Shift focus of development from large-scale products to value-added drug formulations. Launch two or more products per year which meet clinical needs, niche products, and products related to patent strategies.
	Reduce cost of sales by expanding production at the Vietnam factory (aiming 30% of volume) and cutting manufacturing costs through the addition of high-quality and affordable APIs from overseas while securing stable means of supply.
Manufacture	In support of quality assurance, conduct regular audits of Group manufacturing sites and external manufacturing subcontractors that are in accordance with ministerial ordinances and confirm that production management and quality control are being performed in keeping with the three principles of good manufacturing practice; at Group manufacturing sites, implement raw material management performed through barcode systems or doublechecking policies, annual product quality reviews, and quality risk management.
	Established a Group Pharmaceutical Sales Headquarters that centrally supervise pharmaceutical sales divisions within both the Company and its subsidiary NPI [*] . Slimmed down our organization through the consolidation of branch offices.
Sale	In addition to conventional wholesale channels, adopt a variety of other sales channels (distributors, etc.) for generic drugs and increase opportunities for the direct sale of certain products.
	Invest in digital transformation to support post-COVID-19 workstyles and raise the productivity of corporate activities; through sales force automation, optimize and accelerate PDCA cycles associated with sales activities aimed at persuading medical institutions and other similar organizations to use our products.

Quality Assurance Generic Business

We implemented the following initiatives in response to quality issues associated with the products of other companies:

Special internal investigations

January 2021: Conducted internal investigations at three factories operated by NPI*

At each factory, we conducted investigations into the potential use of incorrect raw materials, the possible presence of procedure manuals containing unapproved instructions, and systems for communicating with superiors when tests and inspections return abnormal values. None of these investigations uncovered any issues.

February 2021: Distributed information to medical professionals

Both Nippon Chemiphar and Nihon Pharmaceutical Industry Co., Ltd. distributed information regarding supervisory and production management systems to medical professionals.

Enhancement of management systems

Personnel changes effected on April 1, 2021

We strengthened our management's commitment to quality by appointing a Chief Pharmaceutical Officer. Setting common quality standards for the Group

We will set common good manufacturing practice standards for the entire Group and strive to strengthen our quality assurance system through efforts aimed at unifying separate quality assurance systems throughout the Group.

Development of New Applications for Alkalizer

We are conducting multi-faceted development using technologies and expertise related to alkalinization that we cultivated over many years through our involvement with urine Alkalizer.

For pharmaceuticals

Anti-cancer agent DFP-17729 moves to phase 2a clinical trial

DFP-17729 which we concluded a licensing agreement with drug discovery venture Delta-Fly Pharma, Inc. conducts clinical trial for patients suffering from late-stage pancreatic cancer. In April 2021, it moved to phase 2a.

Promote clinical research for preventing progress of chronic kidney disease

We are currently utilizing AI and clinical data to conduct additional analysis of results generated by the CKOALA study conducted at Tohoku University, which focused on the renoprotective effects of oral alkalizers in patients of chronic kidney disease. We expect to be presented the results of these analyses at conferences within FY2021 and seek possibility to expand indication.

Investigation regarding possible applications in functional foods and health foods

Based on research data and our expertise regarding alkalization therapy, we are also developing functional foods with domestic food manufacturers and plan to launch during 2022-2025.



Pipeline

т 1	1	1 1	1
In-house	driig	devel	onmen
III IIOuse	urue		

nt lg γp

Other companies or physician-initiated development

Item	Function (Target)	Pre- clinical	Phase 1	Phase 2	Notes
NC-2400	PPAR-δ agonist (Lipid metabolism abnormalities)				Finished Phase 1.Licensed to Abionyx Pharma SA (France).
NC-2500	XOR inhibitor (Hyperuricemia, gout)				 Phase1 was finished and we are conducting licensing out activities. Explored possibilities for applications as a treatment for neurodegenerative diseases.
NC-2600	P2X4 receptor antagonist (Neuropathic pain)				 Phase 1 was finished and we are conducting licensing out activities. Also began out-licensing for application as a treatment for chronic coughing.
NC-2700	URAT1 inhibitor (Hyperuriceia, gout)				•Finished preclinical trial and we are conducting licensing out activities.
NC-2800	δ opioid receptor agonist (Depression/Anxiety)				 Selected by AMED for its funding program on January 2018. Conducting out-licensing activities ahead of a phase 1 clinical trial launch planned for FY2021.
DFP-17729	Cancer microenvironment improving agent (Pancreatic cancer)				Developed by Delta-Fly Pharma, Inc.From April 2021, moved to phase 2 trial.
Soleton	COX inhibitor (Diffuse-type tenosynovial giant cell tumor and others)				 Physician-initiated clinical trial was started. Achieved the objective number of trial participants and plan to conduct data analysis.
Calvan	A1β1 blocker (Huntington's disease)				 Licensed to SOM Biotech SL (Spain). Finished phase 2a trial.

Diagnostics Business

We have begun to consider an overseas rollout of DropScreen[™] as we strive to expand its application within the domestic market. Additionally, we have begun collaborating with local partners as we promote allergy testing reagent Oriton IgE Chemiphar[™] in China.

Launched allergy screening kit Drop ScreenTM in Japan

- Breakthrough measuring equipment that is capable of screening blood samples taken from fingertips for 41 allergens within 30 minutes.
- •We received a favorable volume of inquiries from medical institutions considering implementation of the system despite restrictions placed on informative activities by the COVID-19 pandemic.
- •During FY2021, we plan to start specific consideration for overseas rollout.

DropScreenTM measureing device A-1



Rollout of IgE NC in China



IgE NC

- Commercial sales have been started in FY2020. Plan to full-scale promotion in FY2021.
- We provide core components and technologies to indigenous companies attempting to localize their production and earn royalty income commensurate with sales revenue.



Oversea Business

Apply our three goals to overseas markets centered on Asia.

Development of Calvan tablets in China

• In 2020, Calvan tablets were included as a standard treatment option in guidelines set by an authoritative Chinese academic society supporting research concerning high blood pressure.





Vietnam factory



lecture for the launching Calvan tablets. (April 2021, Chengdu City in China)

- Develop channels with the goal of executing sales in Vietnam where our factory is located and in neighboring countries
- Begin development of pharmaceutical products targeting ASEAN markets through Nippon Chemiphar Vietnam



For further information contact:

Public Relations Department, Nippon Chemiphar Co., Ltd. E-mail: ir@chemiphar.co.jp

Note about Forward-looking Statements and Forecasts

Statements made in this *Highlights of Business Results*, with respect to current plans, estimates, strategies and beliefs, and other statements of Nippon Chemiphar that are not historical facts are forward-looking statements about the future performance of Nippon Chemiphar.

These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. Consequently, undue reliance should not be placed on these statements.

Nippon Chemiphar cautions the reader that a number of important factors could cause actual results to differ materially from those discussed in the forward-looking statements.

